What Neurocept products are currently in clinical trials and what conditions are they targeting?

1. What the supplied reporting actually covers — and what it doesn’t

The documents returned by your query focus on broad neurotherapeutics topics (clinical-trial training and conferences), clinical-trial funding impacts, and a newswire-style product announcement for a brain-support supplement called “Neurocept”; none provide an authoritative trial registry entry, company pipeline page, or peer-reviewed clinical-trial report listing Neurocept products in active clinical trials ^{[3] [5] [6] [1]}. On Alzheimer’s pipeline size and trial-count context, detailed academic tracking exists — but it does not tie to Neurocept ^[2].

2. The single direct mention of “Neurocept” is a marketing-style release

The only item that explicitly uses the name “Neurocept” in the search results is a GlobeNewswire piece that presents Neurocept as a consumer-facing brain-support supplement and frames it as entering the U.S. wellness market in 2025; that write-up reads like promotional copy and does not claim or document registered clinical trials or IND/regulated drug development for the product ^[1]. That means the available reporting does not support a conclusion that Neurocept’s product is an investigational drug in formal clinical trials.

3. Where you would normally find clinical-trial evidence — absent here

Clinical-trial presence is typically verifiable via registries (e.g., ClinicalTrials.gov), peer-reviewed trial publications, company pipeline pages, or NIH/academic press releases; none of the provided sources supply such registry listings or peer-reviewed trial results for Neurocept products (available sources do not mention Neurocept on clinical trial registries or in peer-reviewed reporting) ^{[2] [4]}. For Alzheimer’s and other neuro programs, systematic pipeline reviews and NIH resources shown in the search set illustrate how trial activity is documented when present ^{[2] [4]}.

4. Context on neurotherapeutics R&D and why pipeline claims need registry evidence

Neurotherapeutics development commonly involves preclinical work, IND filings, and clinical-trial registration; authoritative summaries (for example, the Alzheimer’s pipeline review cited) rely on registries and formal trial documents to count and describe trials ^[2]. The NIH and professional organizations also host training and listings that help verify trial status; the returned items about clinical-trial training and NIH resources show where credible trial information typically appears, but they do not mention Neurocept ^{[3] [5] [4]}.

5. Alternative explanations and possible hidden agendas in the available material

The GlobeNewswire item is promotional in tone and appears engineered to generate market visibility for a wellness product; such releases often emphasize “clinically inspired” language without providing trial registry identifiers or peer-reviewed evidence ^[1]. That suggests the messaging may be marketing-oriented rather than a declaration of formal clinical development. Conversely, the other results — conference listings and journal portals — represent neutral, professional infrastructure where legitimate clinical programs are usually documented ^{[3] [5] [7]}.

6. Recommended next steps to verify Neurocept’s clinical-trial status

To answer your original question definitively, check ClinicalTrials.gov and equivalent registries for “Neurocept” or the sponsoring company name; search FDA IND/approval databases; look for a corporate pipeline page or investor filings from Neurocept and for peer-reviewed trial publications indexed in PubMed. The present search results do not include those authoritative sources, so they cannot confirm trial activity (available sources do not mention Neurocept in those registries or peer-reviewed literature) ^{[2] [4]}.

Limitations: My analysis is strictly limited to the documents you supplied. If you want, I can search broader registries and company filings now to locate any Neurocept trial registrations or clinical-pipeline statements not covered in these sources.